News articles about CVS Health Corporation (NYSE:CVS) have trended positive on Tuesday, Accern reports. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. CVS Health Corporation earned a media sentiment score of 0.25 on Accern’s scale. Accern also gave news headlines about the pharmacy operator an impact score of 46.6317950632574 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

These are some of the headlines that may have impacted Accern Sentiment’s scoring:

CVS Health Corporation (NYSE:CVS) traded down 0.25% during mid-day trading on Tuesday, reaching $83.10. 4,568,200 shares of the company’s stock traded hands. CVS Health Corporation has a 12-month low of $69.30 and a 12-month high of $90.85. The stock has a 50-day moving average price of $79.11 and a 200-day moving average price of $78.98. The stock has a market capitalization of $84.48 billion, a PE ratio of 16.55 and a beta of 0.92.

CVS Health Corporation (NYSE:CVS) last issued its quarterly earnings data on Tuesday, August 8th. The pharmacy operator reported $1.33 EPS for the quarter, topping analysts’ consensus estimates of $1.31 by $0.02. CVS Health Corporation had a net margin of 2.93% and a return on equity of 17.47%. The business had revenue of $45.69 billion during the quarter, compared to analysts’ expectations of $45.36 billion. During the same period last year, the company posted $1.32 EPS. The business’s revenue was up 4.5% on a year-over-year basis. Equities research analysts expect that CVS Health Corporation will post $5.88 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 3rd. Shareholders of record on Tuesday, October 24th will be paid a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 2.41%. CVS Health Corporation’s payout ratio is currently 39.92%.

CVS has been the subject of a number of recent research reports. Jefferies Group LLC reiterated a “hold” rating and issued a $82.00 price objective on shares of CVS Health Corporation in a research note on Friday, June 9th. Vetr upgraded shares of CVS Health Corporation from a “buy” rating to a “strong-buy” rating and set a $87.97 price objective for the company in a research note on Wednesday, May 24th. Cowen and Company reiterated an “outperform” rating and issued a $86.00 price objective on shares of CVS Health Corporation in a research note on Tuesday, June 13th. Royal Bank of Canada initiated coverage on shares of CVS Health Corporation in a research note on Tuesday. They issued an “outperform” rating and a $95.00 price objective for the company. Finally, ValuEngine lowered shares of CVS Health Corporation from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and fifteen have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $90.58.

COPYRIGHT VIOLATION NOTICE: “CVS Health Corporation (CVS) Given Media Impact Rating of 0.25” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.watchlistnews.com/cvs-health-corporation-cvs-given-media-impact-rating-of-0-25/1574225.html.

In other news, CFO David M. Denton sold 237,078 shares of the firm’s stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $79.65, for a total value of $18,883,262.70. Following the completion of the sale, the chief financial officer now owns 141,096 shares in the company, valued at approximately $11,238,296.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Helena Foulkes sold 39,340 shares of the firm’s stock in a transaction dated Friday, September 15th. The stock was sold at an average price of $81.88, for a total transaction of $3,221,159.20. Following the completion of the sale, the executive vice president now owns 84,337 shares of the company’s stock, valued at approximately $6,905,513.56. The disclosure for this sale can be found here. Insiders sold a total of 716,411 shares of company stock valued at $58,277,271 over the last three months. Corporate insiders own 0.61% of the company’s stock.

About CVS Health Corporation

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Insider Buying and Selling by Quarter for CVS Health Corporation (NYSE:CVS)

Receive News & Ratings for CVS Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.